IPO Brief - Week #5 (17 companies going public this week)

Good morning. We have a busy week ahead with 17 companies (11 from the Health Care sector) planned to go public this week (01 Feb - 05 Feb)

LDI loanDepot 2010

Financial Services • 15,000,000 shares • $19.00 - $21.00 • NYSE

loanDepot is an independent retail mortgage lender that provides residential loans, refinance loans, and personal loan products nationwide.

VOR Vor Biopharma 2016

Health Care • 8,823,530 shares • $16.00 - $18.00 • Nasdaq

Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer. It is focused on developing technologies that can enable selective targeting of cancer cells without impacting normal cells. Cell surface-targeted immunotherapies, such as bispecific antibodies, antibody-drug conjugates, and chimeric antigen receptor (CAR) Tcells, generally target both cancer and normal cells, causing substantial toxicities and limiting their potential.

IMCR Immunocore Holdings 2008

Health Care • 8,333,333 shares • $23.00 - $25.00 • Nasdaq

Immunocore is a focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease.

SNSE Sensei Biotherapeutics undefined

Health Care • 5,885,000 shares • $16.00 - $18.00 • Nasdaq

Sensei Biotherapeutics is a clinical-stage biotechnology company specializing in the field of next-generation cancer immunotherapies. The company developing novel biologics therapies targeting key components of the immune system for the treatment of cancers of unmet need.

LABP Landos Biopharma 2017

Health Care • 6,250,000 shares • $15.00 - $17.00 • Nasdaq

Landos Biopharma is a developer of an oral first-in-class therapeutics designed to target autoimmune diseases.The company's therapeutics are novel, locally-acting small molecules targeting inflammatory bowel disease (IBD), crohn's disease (CD) and ulcerative colitis (UC), enabling healthcare providers to cure their patients.

EVAX Evaxion Biotech 2008

Health Care • 2,750,000 shares • $10.00 - $12.00 • Nasdaq

Evaxion Biotech is devoted to the discovery and development of vaccines against cancer and infectious diseases.

TERN Terns Pharmaceuticals 2016

Health Care • 6,250,000 shares • $15.00 - $17.00 • Nasdaq

Terns Pharmaceuticals is a global biopharmaceutical company committed to discovering and developing molecularly-targeted, oral, small molecule drugs to treat liver disease and cancer.

SANA Sana Biotechnology 2018

Health Care • 15,000,000 shares • $20.00 - $23.00 • Nasdaq

Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. Recent scientific advances make it possible to reprogram cells in the body or replace damaged cells and tissues, creating a new class of medicines to treat a broad array of diseases.

BOLT Bolt Biotherapeutics 2015

Health Care • 8,825,000 shares • $16.00 - $18.00 • Nasdaq

Bolt Biotherapeutics is a biotechnology company that develops a platform for cancer immunotherapy. Its platform, Boltbody, is a cancer immunotherapy that consists of immune-stimulating antibody conjugates.

ANGN Angion Biomedica 1998

Health Care • 5,000,000 shares • $14.00 - $16.00 • Nasdaq

Angion Biomedica is a clinical-stage organ restoration biopharmaceutical company focused on renal disease. Its investigational drug BB3 is entering phase 3 for delayed graft function following kidney transplant and phase 2 for acute kidney injury following open-heart surgery using cardiopulmonary bypass.

LHDX Lucira Health 2013

Health Care • 7,812,500 shares • $15.00 - $17.00 • Nasdaq

Lucira Health develops a new class of professional and home-health solutions to help illuminate and elucidate health status to expedite decision-making and treatment. The company's at-home test kit is well suited for home use and the molecular nucleic acid amplification technology is adaptable to COVID-19 detection.

PHVS Pharvaris 2015

Health Care • 6,950,000 shares • $17.00 - $19.00 • Nasdaq

Pharvaris is a clinical-stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other B2 receptor-mediated indications.PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule bradykinin B2 receptor antagonist currently under Phase 1 clinical study.

UGRO urban-gro 2013

Industrial Products • 4,285,714 shares • $10.50 • Nasdaq

urban-gro was founded on the principle of supplying not only the very best in professional cultivation product solutions, but also the knowledge and education required to maximize plant health and economic yield.

ATC Atotech 1993

Materials • 34,146,000 shares • $19.00 - $22.00 • NYSE

Atotech is an international speciality chemicals company, a subsidiary of the French oil and gas company Total S.A.

ONTF ON24 1998

Software & Tech Services • 8,600,977 shares • $45.00 - $50.00 • NYSE

ON24 is the global leader in webinar-based marketing solutions that drive demand generation and customer engagement. Its patented cloud-based platform features an interactive and immersive user interface and industry-leading webinar analytics for events, campaigns and benchmarking.

TIXT TELUS International 1990

Software & Tech Services • 33,333,333 shares • $23.00 - $25.00 • NYSE

TELUS International designs, builds and delivers next-generation digital solutions to enhance the customer experience.

MULG Muliang Viagoo Technology 2014

Software & Tech Services • 10,000,000 shares • $4.00 • Nasdaq

A Chinese manufacturer and distributor of organic fertilizer and agricultural products.

If you have any questions or would like to see more information, just hit the reply button.

And please share it with friends using the links below: